Holen Sie sich die Stockscreener-App
1.35
2.27%
0.03
Handel nachbörslich:
1.36
0.01
+0.74%
Schlusskurs vom Vortag:
$1.32
Offen:
$1.26
24-Stunden-Volumen:
23,277
Relative Volume:
0.37
Marktkapitalisierung:
$5.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.32M
KGV:
-0.1062
EPS:
-12.7107
Netto-Cashflow:
$-7.30M
1W Leistung:
+9.40%
1M Leistung:
-19.64%
6M Leistung:
-28.95%
1J Leistung:
-55.00%
1-Tages-Spanne:
$1.26
$1.35
1-Wochen-Bereich:
$1.15
$1.66
52-Wochen-Spanne:
$0.952
$6.39
Tharimmune Inc Stock (THAR) Company Profile
Firmenname
Tharimmune Inc
Sektor
Branche
Telefon
302-743-2995
Adresse
1200 ROUTE 22 EAST, BRIDGEWATER
Vergleichen Sie THAR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.35 | 6.96M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Tharimmune Inc Aktie (THAR) Neueste Nachrichten
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl - USA Today
Is Tharimmune Inc. a candidate for recovery playMarket Growth Review & Capital Protection Trade Alerts - Newser
Tharimmune Inc. stock trend outlook and recovery pathWeekly Volume Report & Real-Time Market Sentiment Reports - Newser
Tharimmune, Inc. SEC 10-Q Report - TradingView
What risks could impact Tharimmune Inc. stock performanceQuarterly Trade Summary & Fast Entry Momentum Trade Alerts - Newser
News impact scoring models applied to Tharimmune Inc.July 2025 Levels & Low Risk Entry Point Guides - Newser
Applying Wyckoff theory to Tharimmune Inc. stockEarnings Growth Report & Safe Capital Growth Tips - Newser
Tharimmune expands IP portfolio for opioid countermeasure technology By Investing.com - Investing.com Australia
What indicators show strength in Tharimmune Inc.July 2025 Breakouts & Smart Money Movement Tracker - Newser
Military-Grade Fentanyl Protection: Tharimmune's Drug Platform Secures Global Patent Shield Through 2040 - Stock Titan
Using data filters to optimize entry into Tharimmune Inc.July 2025 PostEarnings & Technical Confirmation Alerts - Newser
Multi factor analysis applied to Tharimmune Inc.2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - Newser
What’s the recovery path for long term holders of Tharimmune Inc.2025 Performance Recap & Reliable Volume Spike Trade Alerts - Newser
Using data tools to time your Tharimmune Inc. exit2025 Market Outlook & Momentum Based Trading Signals - Newser
Using data tools to time your Tharimmune Inc. exit [2025 Analyst Calls]AI Driven Price Predictions - Newser
Tharimmune prices $1.74 million direct offering - MSN
Published on: 2025-08-12 04:27:10 - Newser
Chart based analysis of Tharimmune Inc. trendsLong-Term Investment Strategy Impact Analysis - Newser
Using AI based signals to follow Tharimmune Inc.High Return Idea With Technical Filter - Newser
What machine learning models say about Tharimmune Inc.Free Secure Return Focused Investment Plan - Newser
Analyzing drawdowns of Tharimmune Inc. with statistical toolsReal-Time AI Generated Market Forecast - Newser
Using fundamentals and technicals on Tharimmune Inc.Long Term Stock Planner with Safety Checks - Newser
Has Tharimmune Inc. Stock Ever Crashed Historical Volatility ReviewMonthly Trade Result and Signal Summary - Newser
What makes Tharimmune Inc. stock price move sharplyEquity Forecast with Predictive AI Screener - Newser
Tharimmune Appoints Nancy Davis to Board of Directors - The Globe and Mail
Is Tharimmune Inc. showing insider buyingBest Value for High Returns - thegnnews.com
Tharimmune, Inc. Appoints Nancy Davis to Its Board of Directors - MarketScreener
Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery - The Florida Times-Union
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors - Corsicana Daily Sun
Race to Erase MS Founder Who Raised $56M Joins Biotech Board to Fight Addiction Crisis - Stock Titan
Watch for Bullish Crossover in Tharimmune Inc.Alpha Driven Watchlist With Alerts Published - beatles.ru
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants - Asbury Park Press
Finanzdaten der Tharimmune Inc-Aktie (THAR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tharimmune Inc-Aktie (THAR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Parikh Sanam | Director |
Jun 20 '25 |
Buy |
1.45 |
1,000 |
1,450 |
1,770 |
| Appajosyula Sireesh | Chief Executive Officer |
Jun 20 '25 |
Buy |
1.48 |
61,496 |
90,973 |
64,868 |
| Parikh Sanam | Director |
May 15 '25 |
Buy |
1.30 |
770 |
1,001 |
770 |
| MILBY RANDY | CEO |
Dec 19 '24 |
Buy |
2.12 |
4,600 |
9,752 |
17,534 |
| Appajosyula Sireesh | Chief Operating Officer |
Nov 13 '24 |
Buy |
2.02 |
5,000 |
10,096 |
10,758 |
| MILBY RANDY | CEO |
Oct 08 '24 |
Buy |
2.09 |
2,500 |
5,221 |
12,934 |
| Appajosyula Sireesh | Chief Operating Officer |
Oct 08 '24 |
Buy |
1.93 |
5,000 |
9,650 |
16,364 |
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):